Newscope Capital Corporation announce that PharmaTher has entered into an Exclusive Worldwide License Agreement (the "Agreement") with the National Health Research Institutes ("NHRI") for the development and commercialization of a patented combination formulation of FDA-approved ketamine and betaine ("KETABETTM") as a potential next-generation ketamine treatment for mental health, neurological and pain disorders. KETABETTM has shown in clinical research to enhance the antidepressant effect while having the potential to significantly reduce the known negative side effects of ketamine. Side effects such as hallucinations, confusion, memory loss and abuse liability compromise the compliance and potential therapeutic value of ketamine. Through a proprietary microneedle ("MN") patch, KETABETTM aims to empower patients to dose their medication remotely, safely and conveniently rather than being under supervision by a healthcare provider at a certified medical office. KETABETTM MN patch has the potential to incorporate anti-tampering and anti-abuse features because of the combined presence of ketamine and betaine and the delivery format of the product that would parallel the approach used for the tamper-resistant transdermal fentanyl patch.